Reforms to the U.S. drug pricing environment are required, but to improve patients’ health outcomes, reforms must be grounded in a comprehensive understanding of the current drug pricing system. Otherwise, policymakers will make things worse, not better. An important piece by ACSH advisor Dr. Robert Popovian and Wayne Winegarden, Ph.D.
drug price controls
Who funds this research? Most would say it's government, but they'd be wrong. ACSH friend Dr. Robert Popovian, vice president of Pfizer's U.S. Government Relations, discusses this perennially controversial topic.